Experimental Alzheimer’s drug could slow cognitive decline in patients, early results suggest

The study included 257 patients with early symptomatic Alzheimer’s disease; 131 received donanemab, while 126 received a placebo. The researchers found donanemab slowed the decline of cognition and daily function in Alzheimer’s patients by 32% after 76 weeks, compared to those who received a placebo. Taken over 18 months, that 32% slowing of decline could […]